Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising nearly 18% during trading, with a current increase of 11.76% to HKD 2.09, and a trading volume of HKD 10.2188 million [1] Group 1: Company Developments - The details of the "Beijing Universal Health Insurance" for the year 2026 have recently been announced, with three rare disease products from Beihai Kangcheng included [1] - The drug Goreni, which was approved for market release on May 13 this year, made its debut in the "Universal Health Insurance" [1] - Goreni was first prescribed on July 2 at the Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, marking its official entry into clinical application, which is expected to significantly enhance drug accessibility for domestic patients [1]
港股异动 | 北海康成-B(01228)盘中涨近18% 旗下三款罕见病产品均纳入2026年度北京普惠健康保